Plasmax™: Chest - Sternal Closure
Some of the information contained on this webpage pertains to products, indications for use of products and/or therapies that are only available outside the United States and have not been approved or cleared for marketing by the United States Food & Drug Administration.
Hanks JB, Kjaergard HK, Hollingsbee DA. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidized cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003;35(5):439-44.
Summary: In a prospective, randomized, multicenter clinical study, the hemostatic abilities of an autologous fibrin sealant and Surgicel oxidized cellulose were compared in cardiothoracic, general, obstetric and gynaecologic, and vascular surgery. Autologous fibrin sealant use resulted in a significantly shorter time to hemostasis and more successful cases.
Quotation: “… patient-derived sealant is a more reliable and rapidly effective means of controlling bleeding than Surgicel in a wide range of surgical procedures.”
Kjaergard HK, Trumbull HR. Bleeding from the sternal marrow can be stopped using Vivostat patient-derived fibrin sealant. Ann Thorac Surg 2000;69(4):1173-5.
Summary: In a randomized controlled trial, 30 patients were treated with autologous fibrin sealant, randomly applied to the right or left side of the sternum immediately after median sternotomy, with the other side serving as an untreated control. The average time to hemostasis with fibrin sealant was significantly shorter than with control (43 seconds vs. 180 seconds), and complete hemostasis was observed in 24 of 30 of the treated sides vs. only 4 of 30 of control sides.
Quotation: “…patient-derived fibrin sealant may be an effective alternative to bone wax for controlling bleeding from the sternum after median sternotomy.”